EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 575 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... March 31, 2023 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 EMA Recommends a Change to the Terms of the Marketing Authorisation... October 23, 2025 Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... January 2, 2025 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... What to Know About Cancer Clinical Trial Matching Programs Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma
